[go: up one dir, main page]

NO20081045L - Forbindelser og fremgangsmater for behandling av cancer - Google Patents

Forbindelser og fremgangsmater for behandling av cancer

Info

Publication number
NO20081045L
NO20081045L NO20081045A NO20081045A NO20081045L NO 20081045 L NO20081045 L NO 20081045L NO 20081045 A NO20081045 A NO 20081045A NO 20081045 A NO20081045 A NO 20081045A NO 20081045 L NO20081045 L NO 20081045L
Authority
NO
Norway
Prior art keywords
compounds
methods
treating cancer
leukemia
potent
Prior art date
Application number
NO20081045A
Other languages
English (en)
Inventor
Paul Gutsch
Brian Renzelmann
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Publication of NO20081045L publication Critical patent/NO20081045L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer organiske arsen-forbindelser. Mange av disse forbindelser har kraftig in vitro cytotoksisk aktivitet mot en rekke humane tumorcellelinjer, både av faststoff og hematologisk opprinnelse, så vel som mot ondartede blodceller fra pasienter med leukemi.
NO20081045A 2005-07-29 2008-02-28 Forbindelser og fremgangsmater for behandling av cancer NO20081045L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70416305P 2005-07-29 2005-07-29
PCT/US2006/029835 WO2007027344A2 (en) 2005-07-29 2006-07-28 Compounds and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20081045L true NO20081045L (no) 2008-04-25

Family

ID=37809342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081045A NO20081045L (no) 2005-07-29 2008-02-28 Forbindelser og fremgangsmater for behandling av cancer

Country Status (8)

Country Link
US (3) US7968738B2 (no)
EP (2) EP2394702B1 (no)
JP (1) JP4994374B2 (no)
AU (1) AU2006285329B2 (no)
CA (1) CA2617049A1 (no)
ES (2) ES2532666T3 (no)
NO (1) NO20081045L (no)
WO (1) WO2007027344A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394702B1 (en) 2005-07-29 2014-12-31 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US8252773B2 (en) * 2007-11-02 2012-08-28 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
WO2009075870A1 (en) * 2007-12-12 2009-06-18 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
NZ591181A (en) * 2008-08-20 2012-09-28 Ziopharm Oncology Inc Organoarsenic compounds and methods for the treatment of cancer
CN104768875A (zh) 2012-09-20 2015-07-08 于伽·纳拉扬·本德勒 纳米三氧化二砷的生物合成方法及其在治疗包括癌症的疾病中的用途
US20160304546A1 (en) * 2013-12-05 2016-10-20 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
CN107530476A (zh) * 2015-03-12 2018-01-02 般财团法人化学及血清疗法研究所 使用脱细胞化组织的抗粘连材料和代用生物膜
CN107167433A (zh) * 2016-03-07 2017-09-15 天津国际生物医药联合研究院 一种检测氯二甲基砷的方法
WO2019220961A1 (ja) * 2018-05-18 2019-11-21 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
DE69840057D1 (de) 1997-10-15 2008-11-06 Polarx Biopharmaceuticals Inc Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von Krebs des zentralen Nervensystems
EP1964557B1 (en) 1997-11-10 2013-01-02 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
US7022315B2 (en) 2000-04-26 2006-04-04 Oregon Health & Science University Administration of a thiol-based chemoprotectant compound
EP2420229A1 (en) * 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP2394702B1 (en) 2005-07-29 2014-12-31 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
US8252773B2 (en) * 2007-11-02 2012-08-28 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals

Also Published As

Publication number Publication date
EP1919564B1 (en) 2014-11-26
US20070183972A1 (en) 2007-08-09
US8334398B2 (en) 2012-12-18
ES2532666T3 (es) 2015-03-30
US20120022229A1 (en) 2012-01-26
AU2006285329A2 (en) 2008-08-14
US7968738B2 (en) 2011-06-28
US8865764B2 (en) 2014-10-21
HK1117780A1 (en) 2009-01-23
EP2394702A1 (en) 2011-12-14
EP2394702B1 (en) 2014-12-31
AU2006285329B2 (en) 2012-10-04
US20130142730A1 (en) 2013-06-06
AU2006285329A1 (en) 2007-03-08
WO2007027344A2 (en) 2007-03-08
WO2007027344A3 (en) 2007-12-21
EP1919564A2 (en) 2008-05-14
JP2009502971A (ja) 2009-01-29
HK1164767A1 (en) 2012-09-28
CA2617049A1 (en) 2007-03-08
ES2531159T3 (es) 2015-03-11
JP4994374B2 (ja) 2012-08-08

Similar Documents

Publication Publication Date Title
NO20081045L (no) Forbindelser og fremgangsmater for behandling av cancer
TW200616615A (en) Compounds and methods for the treatment of cancer
WO2011098262A3 (en) P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
IL186104A0 (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
SG151267A1 (en) Carboline derivatives useful in the inhibition of angiogenesis
NO20075918L (no) Substituerte pyrrolo-pyridiner, forbindelser inneholdende disse, fremgangsmate for deres fremstilling og anvendelse derav
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
NZ597075A (en) 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer
WO2006058014A3 (en) Harnessing network biology to improve drug discovery
UA98629C2 (ru) Соединения и способ модуляции киназ
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
RU2711869C3 (ru) Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
WO2005113747A3 (de) Multizelluläre gewebe- und organkultursysteme
BRPI0607306A2 (pt) derivados de quinoxalina como agentes anti-tumor
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
NL2000375A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
MX2009003778A (es) Alimentacion a largo plazo para paciente de cancer.
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
DE602005019762D1 (de) Medizinisches Instrument zum Manipulieren, insbesondere zum Zurückziehen des Gewebes oder des Organes.
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2007118751A3 (de) Verfahren zur veränderung des atp-adp-verhältnisses in zellen
ATE245655T1 (de) Organische-arsenverbindungen
TW200731991A (en) Lipophilic di(anticancer drug) compounds, compositions and related methods

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application